Left ventricular mass behaviour in hemodialysis patients during 17 years

Loren Giagio Cavalcante1, Cavalcante Ricardo de Souza1, Ana Claudia Kochi1

  • 1Universidade Estadual Paulista, BR.

Insights

Left ventricular hypertrophy significantly decreased in hemodialysis patients over 17 years. This reduction was linked to lower blood pressure and improved hemoglobin levels, offering insights into managing cardiac health in dialysis patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Medicine

Background:

  • Left ventricular hypertrophy (LVH) is common in dialysis patients, carrying a poor prognosis.
  • The long-term trend of LVH in hemodialysis patients remains unclear.

Purpose of the Study:

  • To evaluate changes in left ventricular hypertrophy over 17 years in a university dialysis center.
  • To identify potential factors influencing these changes.

Main Methods:

  • A retrospective longitudinal study analyzing echocardiographic left ventricular mass.
  • Included 250 hemodialysis patients aged 18+ years over a 17-year period.

Main Results:

  • A progressive reduction in left ventricular mass was observed during the study period.
  • This reduction correlated with decreased blood pressure.
  • Multivariate analysis showed associations between ventricular mass, blood pressure, and hemoglobin levels.

Conclusions:

  • Significant reduction in left ventricular hypertrophy occurred over 17 years in hemodialysis patients.
  • Progressive blood pressure reduction and increased hemoglobin levels were associated with this decline.
Abstract

Related Concept Videos

Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
1.5K
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.8K
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
3.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580